DUBLIN–(BUSINESS WIRE)–The “Oncology KnowledgeBASE” newsletter has been added to ResearchAndMarkets.com’s offering.
The Oncology KnowledgeBASE provides a comprehensive view of the status of the global oncology drug development and personalized medicine sector in terms of:
- companies developing and marketing therapeutics/in vivo imaging agents and/or in vitro diagnostics
- institutions/non-profits with affiliations/agreements in this sector
- therapeutic agents in development or on the market globally (over 4,500 drugs in development)
- molecular targets of approved drugs and of those currently evaluated in preclinical/clinical trials or identified as playing a role in cancer
- patents, orphan drug status, sales, etc.
New Drugs and Marketed Drugs profiles
The database provides detailed profiles of over 4,500 distinct drugs/in vivo imaging agents in development and on the market by
- developer/affiliate (over 1,000 pipelines)
- generic name/brand name/other designation
- technology
- mechanism of action
- cancer indications; over 100 indications
- clinical indications; hundreds of indications
- administration route
- molecular targets
- biomarker/companion diagnostics
- delivery technology
- development status
- clinical development by phase and status
- clinical history, including trial protocols, interim and final results
- sales history (when available)
Company profiles
The database profiles over 2000 companies in the oncology space in terms of
- history
- management
- financing
- enabling technologies
- affiliations/collaborations/licenses
- pipelines, etc.
Targets in Oncology Profiles
The database profiles over 1,000 molecular targets implicated in cancer and its treatment in terms of
- cancer indication
- utility (treatment, in vivo imaging, in vitro diagnosis, prognosis, disease monitoring
- institution/academic programs
New and Marketed Drugs Module
These modules comprise comprehensive records of thousands of drugs in discovery/research, preclinical and clinical development and those on the market globally. Numerous possible inquiries within these modules include:
- Individual company pipelines
- Company affiliations
- Marketed or novel drugs by target (and by indication, clinical status, technology, mechanism, delivery, etc.)
- Marketed or novel drugs by mechanism (cytotoxics, immunotherapy agents, angiogenesis inhibitors, apoptosis enhancers, gene silencing agents, oncolytics, etc.)
- Marketed or novel drugs by technology (small molecule drugs, monoclonal antibodies, antibody-drug conjugates, immune-oncology agents, fusion proteins, synthetic nucleic acid sequences and RNAi, radioimmunoconjugates, etc.)
- Marketed or novel drugs by drug delivery (liposomes, nanoparticles, PEG, vectors, etc.)
- Marketed or novel drugs by indication (100 different cancer indications and over 2000 clinical indications)
- Novel drugs by phase of clinical development (clinical trials described for over 2000 novel agents, with interim and final results when appropriate)
- Biomarkers associated with the development of new drugs (over 2,160 targeted drugs in clinical/preclinical development
- Marketed drugs by approved indication (over 530 branded drugs)
Company Module
This module profiles thousands of companies spanning the spectrum of small start-ups to multinational biotechnology and pharmaceutical companies developing drugs and personalized medicine tools or providing enabling technologies in this sector. Possible inquiries within these modules include:
- Full address, list of company executives, website links, etc.
- Financings, IPO, mergers, and acquisitions
- Description of enabling technologies
- Affiliations and collaborations worldwide
- Diagnostics/personalized medicine products and services by cancer indication (diagnostics, prognostics, theranostics, disease monitoring methodologies, pharmacogenomics, etc.)
Targets in Oncology Module
This module profiles over 1000 molecular markers relevant in personalized medicine. Numerous possible inquiries within these modules include:
- Marker profile (name, location, description,
- Markers by cancer indication (over 100 indications)
- Markers by expression site (secreted, cell membrane. intracellular, cytoplasm, nucleus, cytosol, etc.)
- Markers incorporated in vitro testing (IVT) assays
Companies Mentioned
- BridgeBio Pharma
- CureVac
- Gilead Sciences
- immatics Biotechnologies
- Intezyne Technologies
- Kitov Pharmaceuticals
- MabVax Therapeutics
- OncoSec Medical
- Sutro Biopharma
For more information about this newsletter visit https://www.researchandmarkets.com/r/twcurc
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900